# A Vaccine for Lymphatic Filariasis, LFGuard™

> **NIH NIH R44** · PAI LIFE SCIENCES, INC. · 2024 · $995,460

## Abstract

PROJECT SUMMARY
Lymphatic filariasis (LF) is one of only a small number of diseases classified as potentially
eradicable. In 1997, the World Health Assembly passed a resolution to eliminate LF as a public
health problem and the approach involved yearly concurrent mass drug administration (MDA)
to the at-risk population in 52 countries. According to the WHO, about 856 million people are
at-risk of acquiring LF and need annual MDA treatment. After over 17 years of MDA to the at-
risk population and spending several billion dollars, the incidence of LF infection has not
significantly declined. This is likely due to subject non-compliance and lack of effectiveness of
the drugs against the adult parasites living within the lymphatic system. Thus, reliance on the
drug therapy approach alone is ineffective in limiting disease transmission. In fact,
chemotherapy only treats current infections and does not prevent future re-infections leaving
the patients susceptible to the disease. Several recent studies show that the disease is re-
emerging in several parts of the world. Therefore, there is a critical need for developing an
effective prophylactic vaccine that can support the current MDA approach for preventing
disease transmission and total elimination of the disease from endemic regions.
Unlike most other infectious organisms such as viruses, bacteria or protozoa, the lymphatic
filarial parasites do not replicate within their definitive hosts. Therefore, the prophylactic
vaccine against LF need not induce sterilizing immunity to be effective for controlling the
infection. In fact, the World Health Organization (WHO) has determined that helminth vaccines
that can prevent worm establishment by 50% will be effective in reducing overall morbidity and
mortality.
Over the last 2 decades, several vaccine candidates were identified and tested for their
therapeutic potential against LF in rodent models. However, none of these candidates
advanced beyond rodent testing - partially because of poor protection and/or lack of resources
to advance the technology. We have developed and established the first successful multivalent
recombinant fusion protein vaccine (BmHAXT) for the prophylaxis of LF. The vaccine gives
close to sterile immunity in rodents and significant protection in non-human primates (70%)
when given along with a TLR4 agonist adjuvant. BmHAXT is now ready to move clinical
development. Thus, the major focus of this project is to perform the remaining IND enabling
activities including (Aim 1) the CMC activities required for regulatory submission and
demonstrating stability of the human use product, (Aim 2) the preclinical animal testing to
confirm that the newly manufactured LFguard™ vaccine maintains its potency in experimental
animal models and that it is safe in a GLP toxicology study, and finally, (Aim 3) write the clinical
and supporting documents and submitting the IND.

## Key facts

- **NIH application ID:** 10822338
- **Project number:** 2R44AI140708-05
- **Recipient organization:** PAI LIFE SCIENCES, INC.
- **Principal Investigator:** DARRICK Albert CARTER
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $995,460
- **Award type:** 2
- **Project period:** 2019-03-01 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10822338

## Citation

> US National Institutes of Health, RePORTER application 10822338, A Vaccine for Lymphatic Filariasis, LFGuard™ (2R44AI140708-05). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10822338. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*